Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Apr;171(4):631-9.
doi: 10.1007/s00431-012-1703-y. Epub 2012 Mar 1.

Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls

Affiliations
Case Reports

Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls

Barbara K Burton et al. Eur J Pediatr. 2012 Apr.

Abstract

Mucopolysaccharidosis II (MPS II), or Hunter syndrome, is an X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase. Affected patients suffer progressive damage to multiple organ systems and early mortality. Two thirds of patients also manifest cognitive impairment and developmental delays. MPS II can be extremely difficult to diagnose before irreversible organ and tissue damage has occurred because of an insidious onset and the overlap in signs and symptoms with common childhood complaints. This is particularly true of patients without cognitive impairment (attenuated phenotype). Although not curative, early treatment with enzyme replacement therapy before irreversible organ damage has occurred may result in the greatest clinical benefit. Here, the signs, symptoms, and surgical history that should trigger suspicion of MPS II are described, and the diagnostic process is reviewed with a focus on practical considerations and the avoidance of common diagnostic pitfalls. Once a diagnosis is made, multidisciplinary management with an extended team of pediatric specialists is essential and should involve the pediatrician or family practice physician as facilitator and medical home for the patient and family.

Conclusion: Because routine newborn screening is not yet available for MPS II, the involvement and awareness of pediatricians, family practice physicians, and pediatric specialists is critical for early identification, diagnosis, and referral in order to help optimize patient outcomes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Coarse facies in a 5-year-old child with MPS II. Note the frontal bossing, heavy eyebrows, puffy eyes, broad “saddle” nose, large jowls, thick lips, and enlarged tongue
Fig. 2
Fig. 2
Patient D (attenuated phenotype) at 13 years of age. Note that the coarse facies are more subtle than seen in patients with the severe phenotype
Fig. 3
Fig. 3
Skeletal manifestations of MPS II: a 33° scoliosis with coarseness of the bones and widening of the ribs in a 16-year-old patient with attenuated MPS II; b magnetic resonance imaging demonstrating mild thoracolumbar kyphosis and typical anterior vertebral body deficiency in a 16-year-old patient with attenuated MPS II; c significant thoracolumbar kyphosis in a 4-year-old patient with severe MPS II; d caput valgum and mild femoral head uncoverage in a 9-year-old patient with severe MPS II; e J-shaped sella in a 21-month-old patient with MPS II; f severe delay in maturation compatible with 3–6 months of age, mild proximal tapering of the metacarpals, and minimal slenderness of the distal phalanges in a 21-month-old patient with MPS II. Images ad reproduced with permission from White et al. [45]
Fig. 4
Fig. 4
Diagnostic algorithm for MPS II

References

    1. Altarescu G, Renbaum P, Eldar-Geva T, Brooks B, Varshaver I, Avitzour M, Margalioth EJ, Levy-Lahad E, Elstein D, Epsztejn-Litman S, Eiges R (2011) Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line. Prenat Diagn 31:853–860 - PubMed
    1. Bach G, Eisenberg F, Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci USA. 1973;70:2134–2138. doi: 10.1073/pnas.70.7.2134. - DOI - PMC - PubMed
    1. Cathey SS, Leroy JG, Wood T, Eaves K, Simensen RJ, Kudo M, Stevenson RE, Friez MJ. Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands. J Med Genet. 2010;47:38–48. doi: 10.1136/jmg.2009.067736. - DOI - PMC - PubMed
    1. Chamoles NA, Blanco M, Gaggioli D. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem. 2001;47:780–781. - PubMed
    1. Chih-Kuang C, Shuan-Pei L, Shyue-Jye L, Tuen-Jen W. MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes. J Clin Lab Anal. 2002;16:253–258. doi: 10.1002/jcla.10051. - DOI - PMC - PubMed

Publication types

LinkOut - more resources